Your browser is no longer supported. Please, upgrade your browser.
ALNY Alnylam Pharmaceuticals, Inc. daily Stock Chart
Alnylam Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-8.14 Insider Own0.50% Shs Outstand112.70M Perf Week-0.65%
Market Cap15.00B Forward P/E- EPS next Y-4.74 Insider Trans-39.25% Shs Float109.86M Perf Month12.83%
Income-886.10M PEG- EPS next Q-1.88 Inst Own97.20% Short Float4.57% Perf Quarter43.56%
Sales219.80M P/S68.26 EPS this Y-7.00% Inst Trans-1.27% Short Ratio6.87 Perf Half Y62.06%
Book/sh12.87 P/B10.34 EPS next Y33.40% ROA-36.70% Target Price138.63 Perf Year71.22%
Cash/sh13.63 P/C9.77 EPS next 5Y46.09% ROE-55.80% 52W Range65.81 - 134.51 Perf YTD15.59%
Dividend- P/FCF- EPS past 5Y-10.80% ROI-65.40% 52W High-3.33% Beta2.50
Dividend %- Quick Ratio4.70 Sales past 5Y34.20% Gross Margin88.60% 52W Low97.59% ATR5.01
Employees1323 Current Ratio4.90 Sales Q/Q241.40% Oper. Margin- RSI (14)60.24 Volatility3.35% 4.17%
OptionableYes Debt/Eq0.00 EPS Q/Q-18.10% Profit Margin- Rel Volume0.41 Prev Close133.12
ShortableYes LT Debt/Eq0.00 EarningsFeb 06 BMO Payout- Avg Volume729.88K Price130.04
Recom1.90 SMA205.46% SMA508.54% SMA20042.87% Volume205,732 Change-2.32%
Dec-19-19Reiterated Chardan Capital Markets Buy $150 → $190
Nov-20-19Initiated Oppenheimer Outperform $128
Nov-13-19Initiated BofA/Merrill Buy $110
May-23-19Resumed Goldman Neutral $80
Apr-12-19Initiated Evercore ISI Outperform
Mar-06-19Upgrade Evercore ISI In-line → Outperform
Mar-05-19Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-23-19Initiated UBS Neutral $87
Oct-01-18Initiated Cantor Fitzgerald Overweight $135
Aug-13-18Reiterated Stifel Buy $125 → $123
Aug-07-18Upgrade Stifel Hold → Buy $95 → $125
May-04-18Reiterated Stifel Hold $107 → $95
Mar-28-18Initiated Evercore ISI In-line
Mar-26-18Reiterated JMP Securities Mkt Outperform $169 → $207
Feb-16-18Reiterated B. Riley FBR, Inc. Buy $205 → $200
Jan-08-18Reiterated B. Riley FBR, Inc. Buy $220 → $205
Nov-09-17Upgrade JP Morgan Neutral → Overweight
Nov-08-17Reiterated Barclays Overweight $127 → $158
Nov-08-17Reiterated B. Riley FBR, Inc. Buy $240 → $220
Nov-03-17Reiterated Needham Buy $125 → $152
Feb-20-20 08:00AM  Alnylam to Webcast Presentation at 9th Annual SVB Leerink Global Healthcare Conference Business Wire
Feb-18-20 08:00AM  Pfizer Stock Tumbled On Lackluster Earnings Should You Add Shares? Investor's Business Daily
07:00AM  Alnylam Completes Enrollment of HELIOS-A Phase 3 Study of Vutrisiran for the Treatment of hATTR Amyloidosis with Polyneuropathy Business Wire
Feb-11-20 05:54PM  Drug makers tap genetic test to save kids with seizures American City Business Journals
Feb-10-20 08:44PM  Edited Transcript of ALNY earnings conference call or presentation 6-Feb-20 1:30pm GMT Thomson Reuters StreetEvents
Feb-07-20 09:25AM  Alnylam's (ALNY) Q4 Earnings Miss Estimates, Sales Beat Zacks
Feb-06-20 08:00AM  Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Period Activity Business Wire
06:30AM  Alnylam Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Feb-05-20 04:03PM  In the highest ranks of Mass. corporate leadership, women still scarce American City Business Journals
Jan-31-20 06:00AM  Alnylam Receives Positive CHMP Opinion for GIVLAARI (givosiran) for the Treatment of Acute Hepatic Porphyria in Adults and Adolescents Business Wire
Jan-30-20 12:31PM  Earnings Preview: Alnylam Pharmaceuticals (ALNY) Q4 Earnings Expected to Decline Zacks
Jan-29-20 12:02PM  Industry vet Holtzman steps down; Decibel retunes strategy American City Business Journals
Jan-28-20 10:39AM  Regeneron & Sanofi's sBLA for Dupixent Accepted by the FDA Zacks
Jan-27-20 04:00PM  Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2019 Financial Results Business Wire
Jan-16-20 05:29AM  Are Investors Undervaluing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) By 46%? Simply Wall St.
Jan-15-20 05:39AM  Alexion pushes 'high-risk, high-reward' ALS strategy amid competitive pressure American City Business Journals
Jan-13-20 10:17AM  Alnylam Provides Preliminary Q4 Sales for Onpattro & Givlaari Zacks
Jan-12-20 06:00PM  Alnylam Announces Preliminary* Fourth Quarter and Full Year 2019 Global Net Product Revenues and Provides Additional Commercial Updates Business Wire
Jan-10-20 04:00PM  Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 (PH1) Business Wire
02:20PM  Cambridge startup raises $110M for re-doseable gene therapies American City Business Journals
07:00AM  Biogen signs neuro disease drug deal with Cambridge startup American City Business Journals
Jan-08-20 09:28AM  How Did Alnylam Pharmaceuticals, Inc. (ALNY) Compare Against Top Hedge Fund Stocks in 2019? Insider Monkey
Jan-07-20 08:40AM  These 3 Healthcare Stocks Are Set to Soar in 2020, Says Cowen TipRanks
Jan-06-20 07:00AM  Alnylam to Webcast Presentation at 38th Annual J.P. Morgan Healthcare Conference Business Wire
Jan-01-20 07:40AM  We've made it to 2020. These are the top business issues to look for in the new year American City Business Journals
Dec-30-19 10:23AM  Alnylam Stock Up More Than 61% YTD on Pipeline Progress Zacks
09:35AM  Is iShares MSCI USA Equal Weighted ETF (EUSA) a Strong ETF Right Now? Zacks
Dec-26-19 05:00AM  Pharma Companies Are Rushing to Treat a Little-Known Liver Disease. Investors Should Be Skeptical.
Dec-24-19 07:30AM  10 Biotech M&A Targets Under The Scanner For 2020 Benzinga
Dec-18-19 08:50AM  Alnylam's Kidney Disease Drug Succeeds in Late Stage Study Zacks
Dec-17-19 04:12PM  Biotech Succeeds With Gene-Silencing Drug But Its Stock Rally Fails Investor's Business Daily
09:50AM  Alnylam's shares rise on late-stage rare disease results MarketWatch
07:00AM  Alnylam Reports Positive Topline Results from ILLUMINATE-A Phase 3 Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 Business Wire
Dec-16-19 03:42PM  Pfizer Gets CHMP Nod for Vyndaqel Label Expansion in Europe Zacks
Dec-13-19 12:00PM  Here's Why Momentum Investors Will Love Alnylam Pharmaceuticals (ALNY) Zacks
12:00PM  Alnylam (ALNY) Moves to Buy: Rationale Behind the Upgrade Zacks
09:15AM  Guest Host Tonight Zacks
Dec-11-19 05:29AM  Sanofi to restructure Newton diabetes startup Onduo, saying it 'over-invested' American City Business Journals
Dec-04-19 05:31PM  Trade of the 2020's: Sell Gold, Buy Biotech Zacks
Dec-03-19 04:54PM  Alnylam Pharmaceuticals, Inc. (ALNY): These Hedge Funds Cashed Out Too Early Insider Monkey
Dec-02-19 08:12AM  Alnylam Pharmaceuticals (NASDAQ:ALNY) Is In A Strong Position To Grow Its Business Simply Wall St.
Nov-29-19 11:30AM  The Zacks Analyst Blog Highlights: GLD, CRSP, GBT, ALNY and ARKG Zacks
09:34AM  Alnylam Gets Second Product Approval Amid Stiff Competition Zacks
Nov-27-19 05:33PM  Why Gold is Headed to Zero -- And What You Should Buy Instead Zacks
Nov-26-19 09:39AM  Alnylam Pharmaceuticals, Inc. (ALNY) Shares March Higher, Can It Continue? Zacks +5.91%
08:00AM  Alnylam to Webcast Presentations at Upcoming December Investor Conferences TEST Business Wire Releases
08:00AM  Alnylam to Webcast Presentations at Upcoming December Investor Conferences Business Wire
Nov-25-19 09:42AM  The Medicines Company to be Acquired by Novartis for $9.7B Zacks +5.15%
08:37AM  Novartis Is Buying The Medicines Company for $9.7 Billion
Nov-22-19 07:00AM  Alnylam Announces 2020 Product and Pipeline Goals and Provides Updates at R&D Day Business Wire
Nov-21-19 09:54AM  Alnylam's Givosiran Gets FDA Nod for Acute Hepatic Porphyria Zacks
09:01AM  Alnylam (ALNY) Catches Eye: Stock Jumps 10.5% Zacks
07:22AM  The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon Benzinga
Nov-20-19 04:53PM  Alnylam shares jump on FDA approval MarketWatch +10.50%
02:21PM  Alnylam Announces New and Enhanced Framework for Value-Based Agreements to Accelerate Patient and Provider Access to GIVLAARI (givosiran) Business Wire
02:03PM  Alnylam Announces Approval of GIVLAARI (givosiran) by the U.S. Food and Drug Administration (FDA) Business Wire
01:22PM  UPDATE 2-Alnylam's rare genetic disorder drug priced at $575,000 per year Reuters
01:02PM  FDA gives early OK to Alnylam rare disease drug American City Business Journals
12:47PM  U.S. FDA approves Alnylam's drug for rare genetic disorder Reuters
08:41AM  Medicines Company Up on Rumors of Potential Buyout by Novartis Zacks
Nov-19-19 08:00AM  Alnylam Announces Second Annual Advocacy for Impact Grants Program Business Wire +5.61%
Nov-18-19 10:27AM  Medicines Company Posts Full Inclisiran Data From ASCVD Study Zacks
Nov-12-19 04:00PM  Alnylam to Webcast Presentation at Stifel 2019 Healthcare Conference Business Wire
Nov-09-19 12:00PM  Alnylam Initiates ILLUMINATE-C Phase 3 Study of Lumasiran for the Treatment of Advanced Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label Extension Study Business Wire
Nov-07-19 10:00AM  Alnylam Pharmaceuticals (ALNY) is a Great Momentum Stock: Should You Buy? Zacks
Nov-06-19 09:00AM  Alnylam (ALNY) Upgraded to Buy: Here's Why Zacks
04:08AM  Edited Transcript of ALNY earnings conference call or presentation 31-Oct-19 12:30pm GMT Thomson Reuters StreetEvents
Nov-05-19 11:56AM  Regeneron's (REGN) Q3 Earnings Beat on Dupixent Strength Zacks
Nov-01-19 10:34AM  Alnylam's (ALNY) Q3 Earnings and Revenues Beat Estimates Zacks
Oct-31-19 11:54AM  Medicines Company (MDCO) Incurs Wider-Than-Expected Q3 Loss Zacks
09:15AM  Alnylam Pharmaceuticals (ALNY) Reports Q3 Loss, Tops Revenue Estimates Zacks
08:00AM  Alnylam Pharmaceuticals Reports Third Quarter 2019 Financial Results and Highlights Recent Period Activity Business Wire
06:30AM  Dicerna ropes in Roche on gene-silencing deal worth up to $1.67B American City Business Journals
Oct-30-19 12:44PM  Guardant Health (GH) to Report Q3 Earnings: What's in Store? Zacks
08:30AM  Why Earnings Season Could Be Great for Alnylam (ALNY) Zacks
Oct-29-19 09:46AM  Catalyst Pharma (CPRX) to Post Q3 Earnings: What's in Store? Zacks
Oct-25-19 12:12PM  Will Nuplazid Aid Growth for ACADIA (ACAD) in Q3 Earnings? Zacks
Oct-24-19 02:11PM  Alnylam Named #1 Biopharma Employer by Science Magazine Business Wire
10:32AM  Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
10:06AM  Alkermes' (ALKS) Earnings and Sales Beat Estimates in Q3 Zacks
Oct-23-19 08:00AM  Alnylam to Webcast Conference Call Discussing Third Quarter 2019 Financial Results Business Wire
Oct-22-19 04:05PM  Hedge Funds Have Never Been More Bullish On Alnylam Pharmaceuticals, Inc. (ALNY) Insider Monkey
Oct-16-19 09:15AM  Earnings Season Makes Good First Impression Zacks
Oct-15-19 06:00AM  Alnylams Distinguished Chemist Mano Manoharan Receives Lifetime Achievement Award from the Oligonucleotide Therapeutics Society Business Wire
Oct-10-19 07:30AM  Alnylam Announces Filing for Marketing Authorization of ONPATTRO® (patisiran) in Brazil for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy Business Wire
Oct-01-19 06:31AM  With eyes on IPO, muscular dystrophy startup names new CEO American City Business Journals -7.35%
Sep-27-19 07:27AM  If You Had Bought Alnylam Pharmaceuticals (NASDAQ:ALNY) Shares Three Years Ago You'd Have Made 14% Simply Wall St.
Sep-26-19 12:05PM  Medicines Company's Inclisiran Succeeds in Pivotal Studies Zacks
08:30AM  Alnylam to Webcast Presentation at 2019 Cantor Global Healthcare Conference Business Wire
Sep-23-19 12:08PM  Regeneron/Sanofi Gets Positive CHMP Opinion for Dupixent Zacks
Sep-19-19 11:02AM  Alnylam Focuses on Pipeline Development Amid Competition Zacks
Sep-17-19 10:27AM  Alnylam Begins Phase III Study on Onpattro for New Indication Zacks
Sep-16-19 07:30AM  Alnylam Pharmaceuticals Announces Initiation of APOLLO-B Phase 3 Study of Patisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy Business Wire
Sep-13-19 09:00AM  What Makes Alnylam (ALNY) a New Buy Stock Zacks
07:30AM  Alnylam Presents New Evidence Demonstrating Significant Association of V122I, a Highly Prevalent, Pathogenic Transthyretin (TTR) Mutation, with Clinical Diagnosis of Polyneuropathy Business Wire
Sep-11-19 08:30AM  1,000 Alnylam Employees Across the Globe Volunteer at 5th Annual Community Service Day Business Wire
Sep-10-19 05:30AM  Alnylam Presents New Clinical Results for Givosiran at the 2019 International Congress on Porphyrins and Porphyrias Business Wire
Sep-09-19 09:31AM  3 Biotech Stocks That Could Soar This Week Motley Fool
Sep-06-19 03:06PM  Why Amgen's Spending Billions to Buy This 1 Drug; Plus Heart Disease Has a New Enemy Motley Fool
07:30AM  Alnylam to Host Sixth Annual RNAi Roundtable Webcast Series Business Wire
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases. It provides ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. The company's development programs include Vutrisiran, an investigational RNAi therapeutic targeting transthyretin that is in Phase III trials for the treatment of transthyretin-mediated amyloidosis; Givosiran that is in Phase III trials to treat acute hepatic porphyrias; and Lumasiran, an investigational RNAi therapeutic, which is in Phase III clinical trials for glycolate oxidase to treat primary hyperoxaluria type 1. It is also developing Inclisiran, an investigational RNAi therapeutic targeting proprotein convertase subtilisin/kexin type 9 that is in Phase III clinical trials for the treatment of hypercholesterolemia; and Fitusiran, an investigational RNAi therapeutic that is in Phase III clinical trials for treating hemophilia A and B with or without inhibitors. In addition, the company engages in the development of Cemdisiran for complement-mediated diseases; ALN-AAT02 to treat alpha-1 anti-trypsin deficiency-associated liver disease; ALN-HBV02 for treating chronic hepatitis B virus infection; and other earlier-stage programs. Alnylam Pharmaceuticals, Inc. has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Ionis Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SHARP PHILLIP ADirectorFeb 12Option Exercise12.4830,000374,400265,633Feb 13 04:06 PM
SHARP PHILLIP ADirectorFeb 12Sale130.0030,0003,900,000235,633Feb 13 04:06 PM
PAUL STEVEN MDirectorFeb 10Option Exercise14.6730,000440,10031,000Feb 11 04:08 PM
Greenstreet YvonneChief Operating OfficerFeb 10Option Exercise42.225,600236,43211,808Feb 11 04:08 PM
KEATING LAURIEEVP, Chief Legal OfficerFeb 10Option Exercise77.4010,000774,00022,258Feb 12 04:03 PM
KEATING LAURIEEVP, Chief Legal OfficerFeb 10Sale129.0010,0001,290,00012,258Feb 12 04:03 PM
Greenstreet YvonneChief Operating OfficerFeb 10Sale130.009,8921,285,9601,916Feb 11 04:08 PM
PAUL STEVEN MDirectorFeb 10Sale130.0030,0003,900,0001,000Feb 11 04:08 PM
Vaishnaw AkshayPresident, R&DFeb 07Option Exercise42.2222,750960,50534,923Feb 11 04:08 PM
Greenstreet YvonneChief Operating OfficerFeb 07Option Exercise42.226,250263,87512,458Feb 11 04:08 PM
Greenstreet YvonneChief Operating OfficerFeb 07Sale123.906,250774,3756,208Feb 11 04:08 PM
Vaishnaw AkshayPresident, R&DFeb 07Sale125.0023,7082,963,50011,215Feb 11 04:08 PM
KEATING LAURIEEVP, Chief Legal OfficerJan 29Option Exercise77.406,337490,48414,932Jan 31 04:05 PM
KEATING LAURIEEVP, Chief Legal OfficerJan 29Sale119.006,337754,1038,595Jan 31 04:05 PM
KEATING LAURIEEVP, Chief Legal OfficerJan 27Option Exercise42.2234,3741,451,27049,632Jan 29 04:03 PM
KEATING LAURIEEVP, Chief Legal OfficerJan 27Sale117.7041,0374,829,9708,595Jan 29 04:03 PM
Greenstreet YvonneChief Operating OfficerNov 20Option Exercise42.228,404354,81710,320Nov 22 04:05 PM
Fanucci MarshaDirectorNov 20Option Exercise13.8075,0001,035,00075,000Nov 22 04:06 PM
Fanucci MarshaDirectorNov 20Sale100.0075,0007,500,0000Nov 22 04:06 PM
Greenstreet YvonneChief Operating OfficerNov 20Sale105.008,404882,4201,916Nov 22 04:05 PM
SHARP PHILLIP ADirectorNov 18Option Exercise16.4315,000246,450250,633Nov 20 04:17 PM
SHARP PHILLIP ADirectorNov 18Sale91.7115,0001,375,662235,633Nov 20 04:17 PM
Greene Barry EPresidentOct 22Option Exercise16.4358,913967,941111,851Oct 24 04:04 PM
Greene Barry EPresidentOct 22Sale89.9958,9135,301,58152,938Oct 24 04:04 PM
MARAGANORE JOHNChief Executive OfficerOct 14Option Exercise16.4349,456812,562239,449Oct 16 04:06 PM
MARAGANORE JOHNChief Executive OfficerOct 14Sale79.4549,4563,929,210189,993Oct 16 04:06 PM
MARAGANORE JOHNChief Executive OfficerMay 15Option Exercise16.4349,457812,579239,450May 17 04:07 PM
MARAGANORE JOHNChief Executive OfficerMay 15Sale70.0049,4573,461,990189,993May 17 04:07 PM
SHARP PHILIP ADirectorApr 15Option Exercise22.0915,000331,350250,633Apr 17 04:05 PM
SHARP PHILIP ADirectorApr 15Sale88.2315,0001,323,442235,633Apr 17 04:05 PM